TRICON8

TRICON8 is the translational research sub-study of the ICON8 trial. Its aim is to establish a large, comprehensive biobank comprising tumour tissue, blood and serial plasma samples with associated clinical data which will be an invaluable resource for high-quality translational research in ovarian cancer. ICON8 is a phase III randomised controlled trial designed to investigate the safety and efficacy of two dose-dense, dose-fractionated, weekly carboplatin-paclitaxel combination chemotherapy regimens for the treatment of newly diagnosed ovarian cancer compared to standard three-weekly carboplatin-paclitaxel. There is a growing body of evidence that using dose-fractionated paclitaxel in particular may have increased anti-tumour effects, and this is thought to be due to enhanced anti-angiogenic and pro-apoptotic effects.

Existing samples:

  • Malignant tumour of ovary

Bespoke collection capabilities:

  • Malignant tumour of ovary

Contact Information

Email:
mrcctu.icon8and8b@ucl.ac.uk
Address:

Cambridge Cancer Trials Centre
Cambridge Clinical Trials Unit - Cancer Theme
Cambridge University Hospitals NHS Foundation Trust
Box 279 (S4), Addenbrooke's Hospital, Hills Road
Cambridge
Cambridgeshire
CB2 0QQ
UK

Annual Statistics

Year Access Requests Received Access Requests Approved
Internal External Commercial Internal External Commercial
2015 N/A N/A N/A N/A N/A N/A
2016 N/A N/A N/A N/A N/A N/A
2017 N/A N/A N/A N/A N/A N/A
2018 N/A N/A N/A N/A N/A N/A
2019 N/A N/A N/A N/A N/A N/A